1
/
의
1
AntibodySystem
SKU(재고 관리 코드):KDB95602
Gevokizumab ELISA Kit
Gevokizumab ELISA Kit
Catalog No.: KDB95602
| Catalog No. | KDB95602 |
|---|---|
| Product name | Gevokizumab ELISA Kit |
| Size | 96 T |
| Description | PRINCIPLE OF THE ASSAY This assay employs the quantitative competitive enzyme immunoassay technique. Recombinant Human IL1B has been pre-coated onto a microplate. Standards or samples are premixed with biotin-labeled antibody and then pipetted into the wells. Gevokizumab in the sample competitively binds to the pre-coated protein with biotin-labeled Gevokizumab. After washing away any unbound substances, Streptavidin-HRP is added to the wells. Following a wash to remove any unbound enzyme reagent, a substrate solution is added to the wells and color develops in inversely proportion to the amount of Gevokizumab bound in the initial step. The color development is stopped and the intensity of the color is measured. |
| Applications | Used for the quantitative determination of Gevokizumab concentration in serum and plasma. |
| Stability and Storage | When the kit was stored at the recommended temperature for 6 months, the signal intensity decreased by less than 20%. |
| Detection method | Colorimetric |
| Precision | CV<20% |
| Sample type | Plasma, Serum |
| Assay type | Quantitative |
| Sensitivity | 27.51 ng/mL |
| Range | 31.25 - 2,000 ng/mL |
| Recovery | 80-120% |
| Background | Gevokizumab (XOMA-052) was developed by XOMA Ltd., USA and represents a humanized IgG2kappa antibody. XOMA-052 binds to IL-1β with high affinity leading to reduced binding affinity of the cytokine to its signaling receptor. Since gevokizumab does not influence the affinity of IL-1β for its decoy and soluble inhibitory receptors the endogenous regulatory mechanisms involving the clearance and inhibitory receptors also contribute to the effect of the antibody [6]. In August 2012 the FDA granted orphan drug status to gevokizumab for the treatment of noninfectious intermediate uveitis, posterior uveitis, panuveitis, and chronic noninfectious anterior uveitis. A single intravenous injection of the substance was also shown to lead to complete resolution of intraocular inflammation in Behçet’s uveitis. |
| Alternative Names | XOMA 052, CAS: 1129435-60-4 |
| Shipping | 2-8 ℃ |
| Note | For Research Use Only. |
Share
